Quantcast

Industry news that matters to you.  Learn more

Eisai Contracts with Proteome Sciences to Measure Candidate Alzheimer’s Biomarkers

Reading time: < 1 minute

Proteome Sciences has announced that it has been contracted by the Japanese pharmaceutical firm Eisai to provide biomarker services for Alzheimer’s disease.

Christopher Pearce, Chief Executive of Proteome Sciences said:

We are delighted to add Eisai to the growing list of PS Biomarker Services clients. As a global pharmaceutical company, Eisai has the opportunity to select from many contract service organisations and they have recognised the advantages of using our mass spectrometric assay capabilities, acknowledging our strong track record of delivery in biomarker discovery and validation, as well as rapid MS assay development.

Source: Proteome Sciences